MedTrace Logo

Breast Cancer Proteomics and Molecular Heterogeneity

NCT01840293 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1780

Last updated 2025-12-19

No results posted yet for this study

Summary

Primary objective:

The primary objective is to define the proteomic and molecular characteristics of primary and recurrent/ metastatic breast tumours with special focus on the expression of S100 protein and the estrogen receptor (ER), progesterone receptor (PR) and epidermal growth factor receptor 2 (HER2) genes

Secondary objective:

* To expand our understanding of the complex molecular pathways dictating the progression of breast cancer and their response to different treatment regimes.
* To relate proteomic findings to survival data
* To identify potential serum markers of breast cancer progression

Conditions

  • Primary Breast Cancer
  • Recurrent/Metastatic Breast Cancer

Sponsors & Collaborators

  • Cancer Trials Ireland

    lead NETWORK

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2029-12-31
Completion
2038-01-31

Countries

  • Ireland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01840293 on ClinicalTrials.gov